Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease

NCT00744263 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00744263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00744263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2008
Completion date
October 31, 2013
Enrollment
84,496 (actual)
Sites
159

Conditions

As the registry lists them; a condition with its own page is linked.

13-valent pneumococcal vaccine, pneumococcal infections, pneumonia, pneumococcal